ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.00
1.57%
다우존스 지수
38,239.66
0.40%
Bitcoin
63,643.68
0.37%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) 뉴스

REGN Regeneron Pharmaceuticals Inc

883.20
-7.48 (-0.84%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Regeneron Pharmaceuticals Inc REGN 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
-7.48 -0.84% 883.20 13:00:06
개장가 저가 고가 종가 전일 종가
881.72 875.225 887.4794 883.20 890.68
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
25/04/202420:00GLOBERegeneron and Mammoth Biosciences Collaborate to Pursue..
24/04/202423:05GLOBERegeneron to Showcase Progress in Advancing Novel..
23/04/202406:54GLOBERegeneron to Highlight Advances in Genetic Medicine Research..
16/04/202420:18IHMARKETNEWSEricsson Soars with 66% Net Profit Growth; Live Nation Under..
11/04/202420:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
08/04/202405:00GLOBELinvoseltamab Pivotal Data Presented at AACR Reinforce High..
02/04/202405:05GLOBERegeneron to Report First Quarter 2024 Financial and..
25/03/202420:00GLOBERegeneron Provides Update on Biologics License Application..
13/03/202412:55PRNUSHigh School Seniors Win $1.8 Million at Regeneron Science..
13/03/202410:30GLOBEHigh School Seniors Win $1.8 Million at Regeneron Science..
11/03/202420:00GLOBEPraluent® (alirocumab) Injection Receives FDA Approval to..
08/03/202421:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet..
06/03/202406:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/03/202406:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/03/202406:14EDGAR2Form 144 - Report of proposed sale of securities
29/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/02/202406:34EDGAR2Form 144 - Report of proposed sale of securities
27/02/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/02/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/02/202406:07EDGAR2Form 144 - Report of proposed sale of securities
27/02/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/02/202405:25EDGAR2Form 144 - Report of proposed sale of securities
24/02/202406:04EDGAR2Form 144 - Report of proposed sale of securities
23/02/202415:00GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
23/02/202407:10EDGAR2Form 144 - Report of proposed sale of securities
23/02/202406:06EDGAR2Form 144 - Report of proposed sale of securities
21/02/202421:00GLOBELinvoseltamab BLA for Treatment of Relapsed/Refractory..
21/02/202406:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/02/202406:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/02/202414:59GLOBEJapan First in the World to Approve Dupixent® (dupilumab)..
15/02/202407:08EDGAR2Form 144 - Report of proposed sale of securities
13/02/202406:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202408:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/02/202406:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:04EDGAR2Form 144 - Report of proposed sale of securities
10/02/202402:22EDGAR2Form 144 - Report of proposed sale of securities
09/02/202406:56EDGAR2Form 144 - Report of proposed sale of securities
09/02/202406:26EDGAR2Form 144 - Report of proposed sale of securities
09/02/202406:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/02/202406:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/02/202407:59EDGAR2Form 144 - Report of proposed sale of securities
08/02/202407:07EDGAR2Form 144 - Report of proposed sale of securities
08/02/202406:35EDGAR2Form 144 - Report of proposed sale of securities
07/02/202406:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/02/202406:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/02/202406:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/02/202406:05GLOBERegeneron Announces Investor Conference Presentations

최근 히스토리

NASDAQ
REGN
Regeneron Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유